Study wrapper · #895
Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Kanbay M, Shah E, AlShiab R, et al. Diabetes, obesity & metabolism. 2026.
DOI: 10.1111/dom.71106PubMed: 42449480
Editor's note
This meta-analysis of 41 RCTs reports GLP-1-based therapies are associated with a selective anti-inflammatory profile, with two tirzepatide trials specifically showing reduced IL-6. Tirzepatide is a tracked peptide but represents a small slice of the pooled data, and heterogeneity was moderate to high. Effects on IL-6 and TNF-alpha across the broader class were variable, warranting cautious interpretation.
Plain-language abstract
A meta-analysis of 41 trials found GLP-1 and dual GIP/GLP-1 agonists were associated with lower CRP and oxidative stress markers and higher adiponectin, with two tirzepatide trials showing reduced IL-6.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026